Intravenous form of Keppra was approved by US

Belgian pharmaceutical group UCB (UCBBt.BR: Quote, Profile, Research) on Wednesday said U.S. regulators had approved its intravenous formulation of the company's Keppra epilepsy medicine, as an alternative when oral forms of the drug are not appropriate for patients.

The new formulation must be diluted prior to use and administered as a 15-minute intravenous infusion.

Keppra is approved as an add-on therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.